Tumor cell ferroptosis has always been the focus of oncology research. Creative Biolabs offers comprehensive services on the molecular mechanism, ferroptosis-related signaling pathway, ferroptosis relationship with tumor, ferroptosis drug tolerance, and ferroptosis-mediated tumor suppression analysis, to explore new targets, new drugs, and new immunotherapy means.

Introduction to Ferroptosis-mediated Tumor Suppression

Inducing cancer cells to produce ferroptosis can not only inhibit the invasive growth of the tumor itself but also cooperate with other anti-tumor drugs to improve the efficacy of chemotherapy, radiotherapy, or immunotherapy. Creative Biolabs has been focusing on the mechanism of ferroptosis in tumor inhibition, hoping to find molecular therapeutic targets and inhibit tumor growth by regulating the occurrence of ferroptosis in different cancer cells through metabolic pathways and signaling pathways. Our self-developed ferroptosis-based tumor inhibition analysis technology will provide new ideas and new directions for cancer therapy.

Fig.1 The Role of p53 in Suppress or Promote Ferroptosis.¹

Solutions

Malignant tumors are often characterized by the uncontrolled growth and proliferation of transformed cells, so inducing tumor cell ferroptosis is the first cancer treatment strategy to be considered. As a top CRO company in tumor immunotherapy, Creative Biolabs is always looking for new mechanisms to induce cancer cell ferroptosis and inhibit tumor development.

Currently, we offer a range of ferroptosis-mediated tumor suppression analysis services for most types of anti-tumor drugs and their derivatives, from cytotoxicity testing, cell proliferation assay, and cell ROS level detection, to ferroptosis-dependent cell death analysis.

Moreover, we also provide solutions to ferroptosis-mediated tumor resistance mechanisms, establish ways to reduce drug resistance and improve potential chemotherapy efficacy. In our labs, modulating intracellular ROS levels is also one of the common strategies used to reverse drug MDR. Our scientists will use proteomics, metabolomics, and biogenetic analysis techniques to regulate tumor cell Redox responses and intracellular ROS levels to enhance tumor cell ferroptosis to overcome potential MDR mechanisms.

In addition, we have associated DNA damage resulting from chemotherapy radiation with cellular lipid peroxidation and ferroptosis mechanisms, establishing a novel ferroptosis-mediated radiotherapy resistance regulation system. Up to now, we are capable of offering model construction, analysis, and validation services for ferroptosis-mediated radiation-induced tumor cell death.

Recently, our newly established ferroptosis-mediated immunotherapy platform utilizes key molecules related to the immune system and ferroptosis to enhance the immune system's surveillance and clearance of tumors. For example, we down-regulated the expression of SLC3A2 and SLC7A11 by IFN-γ in CD8+ T cells to inhibit the activity of System XC- and induce ferroptosis in tumor cells, which in turn enhanced the damage of tumor cells by CD8+T cells. The emergence of this synergy will provide the basis for the development of new cancer therapies in our company.

Advantages

• New strategies for inducing ferroptosis-dependent cell death in cancer
• Integrated solutions for ferroptosis-mediated drug resistance in tumors
• Targeting regulates the sensitivity of cancer cells to ferroptosis
• Induction of ferroptosis inhibits anti-tumor drug resistance

Creative Biolabs concentrates on the major scientific matters related to the occurrence and development of malignant tumors and the ferroptosis mechanism, and conducts applied basic research, to offer new theories and strategies for tumor drug therapy and facilitating drug innovation. We employ advanced life science technologies like multidimensional omics, in combination with tumor research models, to provide a series of services for the discovery of sensitive markers of ferroptosis-mediated tumor suppression, the analysis of drug resistance mechanisms, and the development of combination drug strategies. If you are interested in our services, please contact us or send us an inquiry.

Reference

1. Gnanapradeepan, Keerthana, et al. "The p53 tumor suppressor in the control of metabolism and ferroptosis." Frontiers in endocrinology 9 (2018): 124.

For Research Use Only | Not For Clinical Use